Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Elias Jabbour(The University of Texas MD Anderson Cancer Center), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Vivian G. Oehler(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Hengbang Wang, Jörge E. Cortes(Augusta University Health), Svetlana Samarina(Kirov Research Institute of Hematology and Blood Transfusion FMBA), Anthony M. Hunter(Emory University), Yifan Zhai(Unknown), Omer Jamy(University of Alabama at Birmingham Hospital), Lixin Jiang(Fudan University), Vera Zherebtsova(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Huanshan Guo, Anna Turkina(National Medical Research Center for Hematology), Cunlin Wang, Olga Uspenskaya(Leningrad Regional Cancer Center), Paul Koller(City of Hope), Vasily Shuvaev(Medical Radiological Research Center), И. Л. Давыдкин(Samara State Medical University), Elza Lomaia(Federal Almazov North-West Medical Research Centre), Dajun Yang(Ascendis Pharma (Denmark)), Zi Chen(Dartmouth College), Sudipto Mukherjee(Cleveland Clinic), Maria R. Baer(U-M Rogel Cancer Center), Tommy Fu
Cited by 26
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
The primary health-care system in China
|The Lancet|2017|1.1k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753